


**CYPHER<sup>®</sup> Stent: Consistently low late loss at 1- and 4-year follow-up**



“This study demonstrates a sustained suppression of neointimal proliferation by sirolimus-eluting Bx VELOCITY<sup>®</sup> stents 1 year after implantation.”

- Sousa JE, et al., *Circulation* (2001)

“This study demonstrates the safety and efficacy of sirolimus-eluting Bx VELOCITY<sup>®</sup> stents 2 years after implantation in humans. In-stent lumen dimensions remained essentially unchanged at 2-year follow-up.... Restenosis “catch-up” was not found in our patient population.”


- Sousa JE, et al., *Circulation* (2003)

“This study confirms the longevity of the optimal outcomes observed in patients treated with sirolimus-eluting Bx VELOCITY<sup>®</sup> stents 4 years after implantation. In-stent lumen dimensions remained essentially unchanged at 4-year follow-up, particularly in the population treated with the currently available SES ([slow-release] formulation).”

- Sousa JE, et al., *Circulation* (2005)

Measurement of late loss is associated with wide variability, as can be seen in standard deviations around each assessment.

**CYPHER<sup>®</sup> Stent: Significantly lower incidence of TLR out to 5 years<sup>1</sup>**



**CYPHER<sup>®</sup> Stent: No significant difference in stent thrombosis out to 5 years<sup>1</sup>**

